Nevanac (Nepafenac)

After instillation, nepafenac penetrates the cornea and is converted by ocular enzymes into amfenac, an active NSAID. Amfenac blocks cyclooxygenase‑1 and cyclooxygenase‑2, lowering prostaglandin production, which in turn diminishes inflammation and pain signals within the eye.

The dosing regimen for Nevanac is determined by the prescribing ophthalmologist. Typically, the doctor will advise the number of drops, frequency, and duration based on the individual patient's surgical outcome and response.

Safety of nepafenac during pregnancy or lactation has not been definitively established. It should only be used if the potential benefit justifies any possible risk to the fetus or infant, and the decision must be made by a qualified health professional.

To order Nevanac, submit an enquiry on the product page at gnhindia.com indicating the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any required import documentation.

Nevanac is a pro‑drug formulation that offers rapid corneal penetration and conversion to the active amfenac, providing effective anti‑inflammatory action with a relatively low incidence of ocular irritation compared with some older NSAID eye drops. Clinical choice depends on physician preference, patient tolerance and specific surgical context.

Nevanac should be stored at room temperature, below 25 °C, in its original container. Keep the bottle tightly closed, protect it from direct light and moisture, and avoid freezing. Do not use the product if the suspension appears discoloured or contains particles.

Nevanac is applied as a sterile eye drop. The patient instills the prescribed number of drops into the affected eye(s) according to the ophthalmologist’s instructions, typically avoiding contact between the dropper tip and the eye or any surface to maintain sterility.

Serious risks, although rare, include corneal ulceration or keratitis, significant increases in intra‑ocular pressure, severe allergic reactions such as angioedema, and sudden vision loss. Any unexpected pain, redness, or visual changes should prompt immediate medical evaluation.

Nevanac should not be used by individuals with known hypersensitivity to nepafenac, amfenac, or any component of the formulation, and it is contraindicated in eyes with active infection. Caution is also advised for patients with a history of severe ocular surface disease.